Ionis Pharmaceuticals
$55.359876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$55.35
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$1.30 (+2.41%) As of 7:48 PM UTC today
Why Robinhood?
You can buy or sell IONS and other stocks, options, and ETFs commission-free!
About IONS
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA. The listed name for IONS is Ionis Pharmaceuticals, Inc. Common Stock.
CEO
Brett P. Monia
Employees
817
Headquarters
Carlsbad, California
Founded
1989
Market Cap
8.35B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
970.51K
High Today
$56.01
Low Today
$53.00
Open Price
$53.92
Volume
641.91K
52 Week High
$64.37
52 Week Low
$39.32
IONS News
Analyst Ratings
48%
of 21 ratings
Buy
48%
Hold
33%
Sell
19%
IONS Earnings
-$0.35
$0.21
$0.77
$1.33
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
$0.28 per share
Actual
$0.81 per share